SCI Pharmtech, Inc. (TPE:4119)

Market Cap	5.58B -34.4%
Revenue (ttm)	1.36B -13.7%
Net Income	95.75M -81.7%
EPS	0.80 -81.6%
Shares Out	119.51M
PE Ratio	58.23
Forward PE	n/a
Dividend	0.75 (1.61%)
Ex-Dividend Date	Jul 1, 2025

Volume	183,332
Average Volume	225,027
Open	47.50
Previous Close	47.30
Day's Range	46.55 - 47.70
52-Week Range	46.55 - 72.40
Beta	0.10
RSI	32.45
Earnings Date	May 15, 2026

About SCI Pharmtech

SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychloroquine sulfate, loxoprofen sodium, methylphenidate HCl, pentobarbital sodium, pimobendan, probucol, propafenone HCI, sodium valproate, thiopental, an...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1987
• Employees: 245
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 4119

Financial Performance

In 2025, SCI Pharmtech's revenue was 1.34 billion, a decrease of -11.81% compared to the previous year's 1.52 billion. Earnings were 107.37 million, a decrease of -79.92%.